29,561 Shares of Twist Bioscience Corporation $TWST Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. bought a new position in Twist Bioscience Corporation (NASDAQ:TWST) in the third quarter, Holdings Channel.com reports. The institutional investor bought 29,561 shares of the company’s stock, valued at approximately $5,712,000.

Several other hedge funds have also modified their holdings of the company. Western Wealth Management LLC purchased a new stake in shares of Twist Bioscience during the first quarter valued at about $31,000. Strs Ohio purchased a new position in shares of Twist Bioscience in the 1st quarter worth approximately $33,000. Root Financial Partners LLC purchased a new position in shares of Twist Bioscience in the 3rd quarter worth approximately $33,000. PNC Financial Services Group Inc. raised its stake in shares of Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after acquiring an additional 453 shares in the last quarter. Finally, Fifth Third Bancorp bought a new position in shares of Twist Bioscience during the 1st quarter worth approximately $54,000.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 8,057 shares of Twist Bioscience stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $1,521,806.16. Following the completion of the sale, the chief financial officer owned 100,576 shares of the company’s stock, valued at approximately $18,996,794.88. The trade was a 7.42% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of Twist Bioscience stock in a transaction dated Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,905,421.44. Following the sale, the senior vice president directly owned 106,632 shares of the company’s stock, valued at approximately $20,140,652.16. This represents a 8.64% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 608,597 shares of company stock valued at $94,672,268 in the last quarter. Insiders own 3.08% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on TWST shares. Canaccord Genuity Group increased their target price on shares of Twist Bioscience from $120.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, October 12th. BWS Financial reaffirmed a “sell” rating and issued a $45.00 price target on shares of Twist Bioscience in a report on Friday, September 18th. Robert W. Baird lifted their price target on shares of Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Barclays upped their price target on Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Finally, Piper Sandler increased their price objective on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $153.00.

Twist Bioscience Trading Down 15.4%

NASDAQ TWST opened at $120.61 on Friday. The company has a fifty day simple moving average of $152.00 and a two-hundred day simple moving average of $90.68. The stock has a market cap of $7.56 billion, a P/E ratio of -54.33 and a beta of 2.25. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $219.71. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The company had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The company’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 earnings per share. On average, analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Key Stories Impacting Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist Bioscience has launched MRD Express, a development that could support its presence in the minimal residual disease testing market. The article also notes the stock is entering earnings week, when investors may look for updates on the product and business outlook. Read More.
• Neutral Sentiment: A separate analysis describes an “undervalued” investment narrative but flags the company’s sales valuation as expensive, presenting a mixed view rather than a clear near-term catalyst. Read More.
• Neutral Sentiment: Four executives and insiders, including CEO Emily M. Leproust, sold a combined 6,677 shares at $135.40. The transactions were reported as covering tax withholding obligations related to equity-award vesting, which makes them less indicative of discretionary selling.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The available headline does not detail the report’s claims, but the coverage appears to have weighed on investor sentiment. Read More.

Twist Bioscience Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.